already has

Review: bio-generic drugs the next five years welcomes the important development opportunities 5-10 nuggets: bio-medicine industry "blowout" German state securities: bio-pharmaceutical industry-start the factory price surveys of drug development and Reform Commission, Qi Lu securities: a focus on innovation the old republic power leveling, Twelve-Five planning prospects of bio-medicine (stock-pickers) first capital securities: bio-pharmaceutical industry-the Twelve-Five in pharmaceutical industry planningBenefit from love Medicine Unit recommended building security: bio-medicine industry sub-sectors differentiation was (stock-pickers) Goldman Sachs Gao hua: Chinese enterprise opportunities and challenges of the global generic drug in the tide (stock-pickers) China Merchants securities: imitation pharmaceutical industry World Council, China's Road (stock-pickers) 10 stocks to meet bio-generic drug development opportunities welcomes the important development opportunity in coming 5-10 bioGeneric drugs have the opportunity to become medical focus of most attention in recent years. A set of data is the most eye-catching: 2010 global sales reached US $ 850 billion in drug market, where biotechnology drugs and generic drugs and record, reached US $ 140 billion and $ 120 billion, respectively. In the United States outside of bio-generic drug sales also exceeded 1 billionUs $. November 25, organised by the biological effects of bio-generics Summit Forum held in Shanghai, Forum around the "bio-pharmaceutical industry trends and key technologies-like" and other topics for in-depth discussion and analysis of comprehensive interpretation. The experts think, 2013, 2014, a group of bio-pharmaceutical patents expire will focus. United States FDA for bio-generic drug legislationAlso announced, and heralded the bio-generics in the next 5-10 year will usher in a significant development opportunity. Experts said China has licensed 13 25 382 different specifications of the products of genetic engineering medicine and genetic engineering vaccine, only 6 9 21 specifications of products belonging to the original, the rest belongs to the clone. In the listed company, hisun pharmaceutical holding handsPfizer, the first sign of joint moshadong of the drugs industry, Ronsard and fosun pharmaceutical group marriage, were seen as representatives of domestic business of bio-generics. It is learnt that the bio-generic drug research and development in our country has a certain basis. Taking Shanghai as an example, already has, huaxin biology, Shanghai Institute of biological products Wanxing bio and other 7 companies have drugs such as interferon, human growth hormone. According to the Shanghai biologicalDeputy Director of the medical technology industry promotion center Fu Daxu describes, "Twelve-Five" period of recombinant cytokine drugs and biological treatment of industrial development, will focus on the innovation of new target cytokine gene therapy, somatic cell therapy and genetic engineering research. Technology Division Technical Advisor Li Xiangming, research fellow of Chinese bio-imitation pharmaceutical companies make recommendations, before the patent expires, Ahead of layout of imitation and increasing indications are the bio-generics opportunity. But whether companies had the opportunity, also is to see whether there are patents, core technology. Strategic partnership and the bio-pharmaceutical company limited, Director Chen Rulei told reporters, according to an authoritative figures released by the forecasters by 2021 the global bio-generic drug to reach 250 billion dollars. He also saidTechnically successful, ranging from commercial success, especially in bio-pharmaceutical area as a whole. Don't just stare at the technical level, equally crucial marketing and channels, to have a marketing effort, business is hopeful. Rui Guozhong, Director of the Centre on Science and technology achievement transformation of Chinese medicine reminders, domestic drug innovation, must consider good business ideas, and innovations in the market,Is not available for innovation, innovation swtor power leveling, innovation for the business. CIC securities believes that specifications such as bio-generic drug market is growing rapidly in Europe and America, recombinant proteins and monoclonal antibody drugs to the bio-generics industry a huge space for development. (. Last. card. Huan. Lucy)